XML 39 R29.htm IDEA: XBRL DOCUMENT v3.20.2
Summary of Significant Accounting Policies (Tables)
 9 Months Ended
Jun. 30, 2020
Accounting Policies [Abstract]  
Restrictions on Cash and Cash Equivalents The following table provides a reconciliation of the total cash, cash equivalents and restricted cash reported on the Condensed Consolidated Balance Sheets to the corresponding amounts reported on the Condensed Consolidated Statements of Cash Flows.
 Cash, Cash Equivalents and Restricted Cash
June 30,
2020		June 30,
2019		September 30, 2019September 30, 2018
Cash and cash equivalents$487.3  $533.7  $447.1  $452.6  
Restricted cash44.5  42.3  63.7  9.6  
Cash, cash equivalents and restricted cash$531.8  $576.0  $510.8  $462.2  
Schedule of Cash and Cash Equivalents The following table provides a reconciliation of the total cash, cash equivalents and restricted cash reported on the Condensed Consolidated Balance Sheets to the corresponding amounts reported on the Condensed Consolidated Statements of Cash Flows.
 Cash, Cash Equivalents and Restricted Cash
June 30,
2020		June 30,
2019		September 30, 2019September 30, 2018
Cash and cash equivalents$487.3  $533.7  $447.1  $452.6  
Restricted cash44.5  42.3  63.7  9.6  
Cash, cash equivalents and restricted cash$531.8  $576.0  $510.8  $462.2  
Shares Used in Computing Basic and Diluted Earnings Per Share
Shares used in computing basic and diluted earnings per share are as follows: 
Three Months Ended
June 30,		Nine Months Ended
June 30,
 2020201920202019
Denominator (thousands of shares):
Weighted-average common shares outstanding — basic (a)208,598  174,759  208,989  174,541  
Incremental shares issuable for stock options and awards (b)377  —  1,020  2,848  
Weighted-average common shares outstanding — diluted208,975  174,759  210,009  177,389  
(a) The three and nine months ended June 30, 2020, reflects the August 2019 issuance of 34,613 shares of UGI Common Stock in connection with the AmeriGas Merger.
(b) For the three and nine months ended June 30, 2020, 7,083 shares associated with outstanding stock option awards were excluded from the computation of diluted earnings per share above because their effect was antidilutive. For the three months ended June 30, 2019, 2,576 of such shares have been excluded as such incremental shares would be antidilutive due to the net loss for the period. For the nine months ended June 30, 2019, 244 shares associated with outstanding stock option awards were excluded from the computation of diluted earnings per share above because their effect was antidilutive.